Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2016; 8(01): 001-004
DOI: 10.4103/0974-2727.176234
Review Article

Aeromonas spp.: An Emerging Nosocomial Pathogen

Priyam Batra
Division of Microbiology, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India
,
Purva Mathur
Division of Microbiology, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India
,
Mahesh C Misra
Department of Surgery, JPNA Trauma Centre, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations Financial support and sponsorship: Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

ABSTRACT

Aeromonads are hallophillic, nonacid fast, nonspore forming, Gram-negative rods which are widely distributed in the soil, foodstuffs, and aquatic environment. Since times immemorial, they are important zoonotic pathogens of poikilotherms but are now emerging as important human pathogens. These emerging enteric pathogens flourish in the water distribution system by forming biofilms. They possess large number of virulence factors including inherent resistance to various antibiotics and ability to form biofilms using quorum sensing. These properties make them easy pathogens for human infections. Aeromonads are important enteric pathogens, but, with the growing level of immunosuppression in the population, they have been associated with various extraintestinal infections, such as skin and soft‑tissue infections, traumatic wound infections, and lower respiratory tract/ urinary tract infections. The average annual incidence of bacteremia in Southern Taiwan due to Aeromonas spp. was 76 cases/ million inhabitants between 2008 and 2010. However, the incidence reported from Western countries is much lower. The case fatality rate among patients with Aeromonas bacteremia ranges from 27.5 to 46%. Aeromonads are universally resistant to the narrow-spectrum penicillin group of antibiotics such as penicillin, ampicillin, carbenicillin, and ticarcillin. They are however susceptible to piperacillin, azlocillin, second and third generation cephalosporins, and carbapenems. Most of the Aeromonas species are susceptible to aminoglycosides, tetracycline, chloramphenicol, trimethoprim‑sulfamethoxazole, quinolones, and monobactams. This manuscript is a comprehensive systematic review of the literature available on Aeromonas spp.

Key words

Aeromonas - emerging pathogen - immunocompetent


Publication History

Article published online:
19 April 2020

© 2016.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • REFERENCES

  • 1 Abott SL. Aeromonas. In: Baron EJ, Pfaller MA, Jorgensen JH, Yolken RH, editors. Mannual of Clinical Microbiology. 8th ed. Washington DC: ASM Press; 2010. p. 701-5.
  • 2 Igbinosa IH, Igumbor EU, Aghdasi F, Tom M, Okoh AI. Emerging Aeromonas species infections and their significance in public health. Scientific World Journal 2012;2012:625023.
  • 3 Slevin NJ, Oppenheim BA, Deakin DP. Aeromonas hydrophila septicaemia and muscle abscesses associated with immunosuppression. Postgrad Med J 1988;64:701-2.
  • 4 Colwell RR, MacDonell MT, DeLey J. Proposal to recognize the family Aeromonadaceae fam. Int J Syst Bacteriol 1986;36:473-7.
  • 5 Tomás JM. The main Aeromonas pathogenic factors. ISRN Microbiol 2012;2012:256261.
  • 6 Kimura M, Araoka H, Yoneyama A. Aeromonas caviae is the most frequent pathogen amongst cases of Aeromonas bacteremia in Japan. Scand J Infect Dis 2013;45:304-9.
  • 7 Janda JM, Abbott SL. The genus Aeromonas: Taxonomy, pathogenicity, and infection. Clin Microbiol Rev 2010;23:35-73.
  • 8 Albert MJ, Ansaruzzaman M, Talukder KA, Chopra AK, Kuhn I, Rahman M, et al. Prevalence of enterotoxin genes in Aeromonas spp. isolated from children with diarrhea, healthy controls, and the environment. J Clin Microbiol 2000;38:3785-90.
  • 9 Chen PL, Ko WC, Wu CJ. Complexity of ß-lactamases among clinical Aeromonas isolates and its clinical implications. J Microbiol Immunol Infect 2012;45:398-403.
  • 10 Wu CJ, Chuang YC, Lee MF, Lee CC, Lee HC, Lee NY, et al. Bacteremia due to extended-spectrum-ß-lactamase-producing Aeromonas spp. at a medical center in Southern Taiwan. Antimicrob Agents Chemother 2011;55:5813-8.
  • 11 von Graevenitz A. The role of Aeromonas in diarrhea: A review. Infection 2007;35:59-64.
  • 12 Tang HJ, Lai CC, Lin HL, Chao CM. Clinical manifestations of bacteremia caused by Aeromonas species in southern Taiwan. PLoS One 2014;9:e91642.
  • 13 Ko WC, Chiang SR, Lee HC, Tang HJ, Wang YY, Chuang YC. In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila. Antimicrob Agents Chemother 2003;47:2217-22.
  • 14 Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty Third Informational Supplement CLSI Document M100-S23. Vol. 33. Wayne, PA: Clinical Laboratory Standards Institute; 2013.